UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): April 29, 2013
PDL BioPharma, Inc.
(Exact name of Company as specified in its charter)
000-19756
(Commission File Number)
|
|
|
|
|
Delaware |
|
94-3023969 |
|
(State or Other Jurisdiction of |
|
(I.R.S. Employer Identification No.) |
|
Incorporation) |
|
|
932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)
(775) 832-8500
(Company’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On April 29, 2013, PDL BioPharma, Inc. (the Company) will distribute to analysts, at their request, a list of the Company’s supplementary protection certificates and the underlying patents. This information is publicly available, but not in a consolidated format as is being distributed. A copy of the list is attached hereto at Exhibit 99.1.
Limitation of Incorporation by Reference
In accordance with General Instruction B.2. of Form 8-K, the information in this report, including the exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
Item 9.01 Financial Statements and Exhibits.
|
Exhibit No. |
Description | |
|
99.1 |
SPC List |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PDL BIOPHARMA, INC. | |||
|
(Company) |
|||
| By: | /s/ John P. McLaughlin | ||
| John P. McLaughlin | |||
| President, Chief Executive Officer and | |||
| Acting Chief Financial Officer | |||
Dated: April 29, 2013
EXHIBIT INDEX
|
Exhibit No. |
Description | |
|
99.1 |
SPC List |
Exhibit 99.1
PDL BioPharma, Inc.
SPC Status Report
|
Country |
Drug |
Underlying Patent No. |
SPC App. No. |
|
Austria |
HERCEPTIN® (Trastuzumab) |
E133452 |
SZ36/2000 |
|
Belgium |
HERCEPTIN® (Trastuzumab) |
EP0451216 |
2000C/026 |
|
Germany |
HERCEPTIN® (Trastuzumab) |
68925536.5 |
10075038.9 |
|
Denmark |
HERCEPTIN® (Trastuzumab) |
PR174317 |
CA 2003 00007 |
|
Spain |
HERCEPTIN® (Trastuzumab) |
2081974T3 |
C200000026 |
|
Finland |
HERCEPTIN® (Trastuzumab) |
FI108797 |
L2002 0008 |
|
France |
HERCEPTIN® (Trastuzumab) |
EP0451216 |
00C0035 |
|
Great Britain |
HERCEPTIN® (Trastuzumab) |
GB0451216 |
SPC/GB00/032 |
|
Greece |
HERCEPTIN® (Trastuzumab) |
1001050 |
20000800025 |
|
Ireland |
HERCEPTIN® (Trastuzumab) |
82755 |
2003/006 |
|
Italy |
HERCEPTIN® (Trastuzumab) |
EP0451216 |
UB2000CCP708 |
|
Luxembourg |
HERCEPTIN® (Trastuzumab) |
EP0451216 |
90676 |
|
Netherlands |
HERCEPTIN® (Trastuzumab) |
EP0451216 |
300023 |
|
Norway |
HERCEPTIN® (Trastuzumab) |
310473 |
SPC/NO2001024 |
|
Portugal |
HERCEPTIN® (Trastuzumab) |
PT 92758 |
79 |
|
Sweden |
HERCEPTIN® (Trastuzumab) |
SE0451216 |
0090024-1 |
|
Austria |
XOLAIR® (Omalizumab) |
E133452 |
SZ42/2005 |
|
Belgium |
XOLAIR® (Omalizumab) |
EP0451216 |
2005C/038 |
|
Switzerland |
XOLAIR® (Omalizumab) |
EP0451216 |
C00451216/04 |
|
Germany |
XOLAIR® (Omalizumab) |
68925536.5 |
122005000057.40 |
|
Denmark |
XOLAIR® (Omalizumab) |
PR174317 |
CA 2005 00051 |
|
Spain |
XOLAIR® (Omalizumab) |
2081974T3 |
C200500046 |
|
Finland |
XOLAIR® (Omalizumab) |
FI108797 |
L20050028 |
|
France |
XOLAIR® (Omalizumab) |
EP0451216 |
05C0046 |
|
Great Britain |
XOLAIR® (Omalizumab) |
GB0451216 |
SPC/GB05/052 |
|
Hungary |
XOLAIR® (Omalizumab) |
211174 |
S0500022 |
|
Ireland |
XOLAIR® (Omalizumab) |
82755 |
2005/031 |
|
Italy |
XOLAIR® (Omalizumab) |
EP0451216 |
UB2006CCP903 |
|
Luxembourg |
XOLAIR® (Omalizumab) |
EP0451216 |
91208 |
|
Netherlands |
XOLAIR® (Omalizumab) |
EP0451216 |
300213 |
|
Norway |
XOLAIR® (Omalizumab) |
310473 |
SPC/NO2005026 |
|
Portugal |
XOLAIR® (Omalizumab) |
PT 92758 |
212 |
|
Sweden |
XOLAIR® (Omalizumab) |
SE0451216 |
0590038-6 |
|
Slovenia |
XOLAIR® (Omalizumab) |
SI 8912489 |
C-200640004 |
|
Austria |
AVASTIN® (Bevacizumab) |
E133452 |
SZ 6/2005 |
|
Belgium |
AVASTIN® (Bevacizumab) |
EP0451216 |
2005C/004 |
|
Switzerland |
AVASTIN® (Bevacizumab) |
EP0451216 |
C00451216/03 |
|
Germany |
AVASTIN® (Bevacizumab) |
68925536.5 |
12 2005 000 007.8 |
PDL BioPharma, Inc.
SPC Status Report
|
Country |
Drug |
Underlying Patent No. |
SPC App. No. |
|
Denmark |
AVASTIN® (Bevacizumab) |
PR174317 |
CA 2005 00006 |
|
Spain |
AVASTIN® (Bevacizumab) |
2081974T3 |
C200500004 |
|
Finland |
AVASTIN® (Bevacizumab) |
FI108797 |
L20050004 |
|
France |
AVASTIN® (Bevacizumab) |
EP0451216 |
05C0004 |
|
Great Britain |
AVASTIN® (Bevacizumab) |
GB0451216 |
SPC/GB05/009 |
|
Hungary |
AVASTIN® (Bevacizumab) |
211174 |
S0500005 |
|
Ireland |
AVASTIN® (Bevacizumab) |
82755 |
2005/007 |
|
Italy |
AVASTIN® (Bevacizumab) |
EP0451216 |
CU-B2005CCP865 |
|
Luxembourg |
AVASTIN® (Bevacizumab) |
EP0451216 |
91 139 |
|
Netherlands |
AVASTIN® (Bevacizumab) |
EP0451216 |
300173 |
|
Norway |
AVASTIN® (Bevacizumab) |
310473 |
SPC/NO2005005 |
|
Portugal |
AVASTIN® (Bevacizumab) |
PT 92758 |
188 |
|
Sweden |
AVASTIN® (Bevacizumab) |
SE0451216 |
0590004-8 |
|
Slovenia |
AVASTIN® (Bevacizumab) |
SI 8912489 |
C-200540007 |
|
Austria |
TYSABRI® (natalizumab) |
E133452 |
SZ26/2006 |
|
Belgium |
TYSABRI® (natalizumab) |
EP0451216 |
2006C/024 |
|
Germany |
TYSABRI® (natalizumab) |
68925536.5 |
122006000036.4 |
|
Denmark |
TYSABRI® (natalizumab) |
PR174317 |
CA 200600022 |
|
Spain |
TYSABRI® (natalizumab) |
2081974T3 |
C200600026 |
|
Finland |
TYSABRI® (natalizumab) |
FI108797 |
L20060010 |
|
France |
TYSABRI® (natalizumab) |
EP0451216 |
06C0028 |
|
Great Britain |
TYSABRI® (natalizumab) |
GB0451216 |
SPC/GB/06/027 |
|
Hungary |
TYSABRI® (natalizumab) |
211174 |
S0600007 |
|
Ireland |
TYSABRI® (natalizumab) |
82755 |
2006/027 |
|
Italy |
TYSABRI® (natalizumab) |
EP0451216 |
C-UB2006CCP929 |
|
Luxembourg |
TYSABRI® (natalizumab) |
EP0451216 |
91272 |
|
Netherlands |
TYSABRI® (natalizumab) |
EP0451216 |
300239 |
|
Norway |
TYSABRI® (natalizumab) |
310473 |
SPC/NO2006009 |
|
Portugal |
TYSABRI® (natalizumab) |
PT 92758 |
235 |
|
Sweden |
TYSABRI® (natalizumab) |
SE0451216 |
0690023-7 |
|
Slovenia |
TYSABRI® (natalizumab) |
SI 8912489 |
C-200640013 |
|
Switzerland |
TYSABRI® (natalizumab) |
EP0451216 |
C00451216/05 |
|
Austria |
LUCENTIS® (Ranibizumab) |
E133452 |
SZ36/2007 |
|
Belgium |
LUCENTIS® (Ranibizumab) |
EP0451216 |
2007C/030 |
|
Bulgaria |
LUCENTIS® (Ranibizumab) |
BG61095 |
07/041 |
|
Germany |
LUCENTIS® (Ranibizumab) |
68925536.5 |
122007000037.5 |
|
Denmark |
LUCENTIS® (Ranibizumab) |
PR174317 |
CA 2007 00029 |
|
Spain |
LUCENTIS® (Ranibizumab) |
2081974T3 |
C200700020 |
PDL BioPharma, Inc.
SPC Status Report
|
Country |
Drug |
Underlying Patent No. |
SPC App. No. |
|
Finland |
LUCENTIS® (Ranibizumab) |
FI108797 |
L20070013 |
|
France |
LUCENTIS® (Ranibizumab) |
EP0451216 |
07C0029 |
|
Great Britain |
LUCENTIS® (Ranibizumab) |
GB0451216 |
SPC/GB07/033 |
|
Hungary |
LUCENTIS® (Ranibizumab) |
211174 |
S070003 |
|
Ireland |
LUCENTIS® (Ranibizumab) |
82755 |
2007/019 |
|
Italy |
LUCENTIS® (Ranibizumab) |
EP0451216 |
UB2007CCP969 |
|
Luxembourg |
LUCENTIS® (Ranibizumab) |
EP0451216 |
91333 |
|
Netherlands |
LUCENTIS® (Ranibizumab) |
EP0451216 |
300279 |
|
Norway |
LUCENTIS® (Ranibizumab) |
310473 |
SPC/NO2007006 |
|
Portugal |
LUCENTIS® (Ranibizumab) |
PT 92758 |
269 |
|
Sweden |
LUCENTIS® (Ranibizumab) |
SE0451216 |
0790030-1 |
|
Slovenia |
LUCENTIS® (Ranibizumab) |
SI 8912489 |
C-200740008 |
3